SNP Genotyping and Analysis Market will generate new growth opportunities 2024-2031
Global SNP genotyping and analysis market is estimated to be valued at US$ 20.2 Billion in 2024, and is expected to reach US$ 80.7 Billion by 2031 exhibiting a CAGR of 21.9% during the forecast period (2024-2031).
SNP genotyping refers to the technique of determining the variation present in a DNA sequence at a specific location known as the SNP site. It is widely used for genetic analysis, disease association studies, population history studies and pharmacogenomics.
Market Dynamics:
The SNP genotyping and analysis market is expected to witness significant growth over the forecast period owing to advancements in sequencing technologies such as next-generation sequencing. NGS platforms provide high-throughput, inexpensive and rapid genotyping which is boosting their adoption. Furthermore, increasing efforts by pharmaceutical companies and diagnostic laboratories to develop personalized medicines based on genetic variations is also fueling market growth. Population genomic studies exploring genetic variations among populations to gain insights into population migrations and evolution are also contributing to higher demand for SNP genotyping.
?????????????? ???????????? ???????? ???? ???????????? ?? https://www.coherentmarketinsights.com/insight/request-sample/3972
Companies covered:?????
Agilent Technologies Inc., F. Hoffmann-La Roche Ltd, Nucleome Informatics Private Limited, Azenta Life Sciences, Bio-Rad Laboratories Inc., Danaher Corporation, Douglas Scientific LLC, AllGenetics & Biology SL, Illumina Inc., Life Technologies Corp., Consultative Group on International Agricultural Research, Avance Biosciences, Genotypic Technology Pvt Ltd, Xelect Ltd, Taconic Biosciences, Inc., Luminex Corp., Promega Corporation, CD Genomics, Synbio Technologies, Thermo Fischer Scientific Inc., Sequenom, PREMIER Biosoft, Fluidigm Corporation, Novacyt, Twist Bioscience, Regeneron Pharmaceuticals, Inc,? NRGene, and LGC Biosearch Technologies, among other prominent players
Segments covered:????????
By Technology: Polymerase Chain Reaction (PCR), Microarray, Next-Generation Sequencing (NGS), Taqman Allelic Discrimination, Pyrosequencing, Others
By Applications: Diagnostics & Forensics, Pharmacogenomics, Agricultural Biotechnology, Breeding &Animal Livestock
领英推荐
Driver: Growth in chronic and infectious diseases driving demand for SNP genotyping
The rise of chronic and infectious diseases globally is driving demand for advanced genotyping techniques like SNP genotyping. Chronic diseases like cancer, cardiovascular diseases, diabetes are on the rise. Early detection and disease risk assessment have become very important for effective treatment and management of such chronic conditions. SNP genotyping allows identification of genetic variations that can increase susceptibility to chronic diseases. This is helping researchers and clinicians better understand disease pathogenesis and develop targeted prevention and treatment strategies. Similarly, continuous mutation of viruses causing infectious diseases is necessitating advanced pathogen genotyping for strain identification, pandemic risk assessment and vaccine development. SNP genotyping is increasingly being used for microbial genotyping applications which is supporting the market growth.
Restrain: Stringent regulations and ethical concerns limitingclinical applications
While technological capabilities are increasing, regulatory oversight and ethical concerns currently limit broader clinical applications of SNP genotyping results. Regulatory approval processes for clinical diagnostic tests are long and stringent. Clinical validity and utility of genotype-disease associations need robust evidence before they can be endorsed for medical decision making. Ethical issues around data privacy, incidental findings and potential effects on insurance underwriting also need addressing. At present, only a limited number of well-studied genomic biomarkers have regulatory approval for clinical use. Translating research discoveries into clinical practice requires demonstrating clear medical benefit over existing standards that is challenging. Such regulatory complexities and ethical concerns restrain wider adoption of SNP genotyping beyond research currently.
Opportunity: Personalized medicine increasing relevance of pharmacogenomics applications
The growing adoption of personalized and precision medicine approaches in healthcare provides significant opportunities for expansion of pharmacogenomics applications of SNP genotyping. Individual genetic variability plays a major role in drug response, with certain genotypes correlating to increased risk of adverse reactions or treatment failure. Pharmacogenomic testing helps identify these high-risk genotypes and guide more targeted therapeutic choices and dosing for improved outcomes. As personalized treatment based on molecular characteristics becomes integral to fields like oncology, cardiology, psychiatry etc., standard implementation of pharmacogenomic testing will increase. This will drive heavy demand for SNP genotyping as the foundation for pharmacogenomics based stratified medicine approaches. Laboratories, diagnostics companies and healthcare systems can capitalize on this opportunity space.
Trends: Transition to large scale population-level biobanking and biobridging efforts
A notable trend in genomics research as well as the precision medicine domain is the large-scale biobanking of human biological samples along with associated phenotypic and health outcome data on a population level. National and international consortiums are building biorepositories containing genetic and health information of hundreds of thousands to millions of individuals. At the same time, efforts are ongoing to develop standardized genomic/phenotypic datasets or “bridges” that enable portability of research findings across diverse populations as well as their clinical translation. SNP genotyping plays a key role in building these genomic resources and enabling biobridging. As more countries invest in strategic biobanking and biobridging programs, extensive genotyping needs will emerge. SNP genotyping market players can position themselves to partner with and support such large-scale, national and global genomic initiatives.
About Us:
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having sales office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 57 countries worldwide. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.